Cardinal Health Posts Double-Digit Profit Growth, Fuels Expansion with $5.3B Acquisitions

Ticker: CAH · Form: DEF 14A · Filed: Sep 16, 2025 · CIK: 721371

Cardinal Health INC DEF 14A Filing Summary
FieldDetail
CompanyCardinal Health INC (CAH)
Form TypeDEF 14A
Filed DateSep 16, 2025
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$550 million, $1.2 billion, $222.6 b, $2.3 b, $675 million
Sentimentbullish

Sentiment: bullish

Topics: Healthcare Services, Pharmaceutical Distribution, M&A, Specialty Pharmacy, At-Home Solutions, Executive Compensation, Corporate Governance

Related Tickers: CAH, MCK, ABC

TL;DR

**CAH is making a smart, aggressive play into specialty and at-home care with massive acquisitions, signaling a strong pivot from lower-margin distribution despite a revenue dip; buy the dip, this is a long-term winner.**

AI Summary

Cardinal Health, Inc. (CAH) experienced a strong and transformative fiscal year 2025, achieving double-digit profit growth across all five operating segments. The company reported GAAP operating earnings of $2.3 billion, an 83% increase year-over-year, and non-GAAP operating earnings of $2.8 billion, a 15% increase. GAAP diluted EPS rose 87% to $6.45, while non-GAAP diluted EPS increased 9% to $8.24. Revenue, however, decreased 2% to $222.6 billion, primarily due to the expiration of pharmaceutical distribution contracts with OptumRx. CAH deployed $5.3 billion for strategic acquisitions, including Integrated Oncology Network (ION), a majority stake in GI Alliance, Urology America, and Advanced Diabetes Supply Group, to expand its Specialty and at-Home Solutions businesses. The company returned over $1.2 billion to shareholders through $750 million in share repurchases and $494 million in dividends, while investing $547 million in capital expenditures. The Board was also refreshed with the addition of Robert Musslewhite and Sudhakar Ramakrishna, enhancing expertise in healthcare technology and cybersecurity.

Why It Matters

This DEF 14A filing reveals Cardinal Health's aggressive strategic pivot towards higher-margin specialty and at-home care markets through significant acquisitions like GI Alliance and Advanced Diabetes Supply Group. For investors, this indicates a clear growth strategy beyond traditional pharmaceutical distribution, potentially leading to enhanced long-term shareholder value despite a 2% revenue dip from the OptumRx contract expiration. Employees in these acquired specialty areas will see increased integration and potential for growth within a larger healthcare services framework. Customers, particularly specialty physicians and at-home patients, can expect expanded services and more integrated care coordination, intensifying competition with other healthcare distributors and service providers.

Risk Assessment

Risk Level: medium — While Cardinal Health reported strong profit growth and strategic acquisitions, the 2% revenue decline to $222.6 billion due to the OptumRx contract expiration highlights customer concentration risk. The $5.3 billion deployed for acquisitions, while strategic, introduces integration risks and significant capital allocation, which could impact short-term financial flexibility if not managed effectively.

Analyst Insight

Investors should closely monitor the integration of the $5.3 billion in acquisitions, particularly the performance of The Specialty Alliance and Advanced Diabetes Supply Group, to ensure these investments translate into sustained profit growth and market share. The strategic shift towards higher-margin specialty and at-home solutions warrants a deeper dive into segment-specific growth metrics in future earnings reports.

Financial Highlights

debt To Equity
Not Specified
revenue
$222.6B
operating Margin
Not Specified
total Assets
Not Specified
total Debt
Not Specified
net Income
$2.3B
eps
$6.45
gross Margin
Not Specified
cash Position
Not Specified
revenue Growth
-2%

Revenue Breakdown

SegmentRevenueGrowth
Pharmaceutical and Specialty SolutionsNot SpecifiedNot Specified
at-Home SolutionsNot SpecifiedNot Specified
Global Medical Products and DistributionNot Specified47%

Executive Compensation

NameTitleTotal Compensation
Not SpecifiedNamed Executive OfficersNot Specified

Key Numbers

Key Players & Entities

FAQ

What were Cardinal Health's key financial highlights for fiscal year 2025?

Cardinal Health achieved $2.8 billion in non-GAAP operating earnings, a 15% increase year-over-year, and non-GAAP diluted EPS of $8.24, up 9%. All five operating segments reported double-digit profit growth, with GMPD segment profit increasing by 47%.

How did Cardinal Health's revenue perform in fiscal 2025 and why?

Revenue for Cardinal Health decreased by 2% to $222.6 billion in fiscal 2025. This decline was primarily attributed to the expiration of the company's pharmaceutical distribution contracts with OptumRx at the end of fiscal 2024.

What strategic acquisitions did Cardinal Health make in fiscal 2025?

Cardinal Health deployed $5.3 billion for acquisitions, including Integrated Oncology Network (ION) in December 2024, a majority stake in GI Alliance in January 2025, and Advanced Diabetes Supply Group in April 2025. These acquisitions expanded its presence in specialty and at-Home Solutions markets.

How is Cardinal Health addressing its strategic focus on maximizing shareholder value?

Cardinal Health is maximizing shareholder value by growing its core businesses, investing in modernization and expansion of its distribution footprint, and making strategic acquisitions in its Pharmaceutical and Specialty Solutions and at-Home Solutions segments. The company also returned over $1.2 billion to shareholders through dividends and share repurchases.

What changes were made to Cardinal Health's Board of Directors in fiscal 2025?

In March 2025, Cardinal Health welcomed Robert Musslewhite and Sudhakar Ramakrishna to the Board, adding expertise in healthcare technology, data analytics, and cybersecurity. Michelle Brennan was appointed Chair of the Governance and Sustainability Committee, and Dave Evans was appointed Chair of the Audit Committee.

What is Cardinal Health's approach to shareholder engagement?

Cardinal Health has a longstanding practice of meeting with shareholders to understand their perspectives. In summer 2025, the company contacted shareholders representing 50% of outstanding shares and met with shareholders representing 32%, with the Board Chairman participating in meetings representing 30% of shares.

What are the key proposals for the Cardinal Health Annual Meeting of Shareholders on November 5, 2025?

Shareholders will vote on the election of 12 director nominees, an advisory vote to approve named executive officer compensation, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year ending June 30, 2026.

How did Cardinal Health's Global Medical Products and Distribution (GMPD) segment perform?

The GMPD segment continued its multi-year transformation, growing segment profit by 47% in fiscal 2025. This follows the business returning to profitability in fiscal 2024, driven by cost optimization and Cardinal Health Brand growth strategies.

What is The Specialty Alliance and its significance for Cardinal Health?

The Specialty Alliance is a new multi-specialty management services organization (MSO) platform launched by Cardinal Health in June 2025, encompassing GI Alliance and the newly established Urology Alliance. It supports approximately 2,200 providers across 28 states and over 450 sites of care, enhancing Cardinal Health's presence in high-priority specialty areas like autoimmune, urology, and oncology.

What are the primary risks highlighted in Cardinal Health's fiscal 2025 performance?

The primary risks include the 2% revenue decline due to the OptumRx contract expiration, indicating customer concentration risk. Additionally, the $5.3 billion deployed for acquisitions, while strategic, introduces integration challenges and significant capital allocation considerations that require careful management.

Risk Factors

Industry Context

Cardinal Health operates in the highly competitive healthcare sector, specifically in pharmaceutical distribution and medical product manufacturing. The industry is characterized by significant consolidation, increasing regulatory scrutiny, and a growing demand for integrated solutions. Trends include a shift towards value-based care, expansion of specialty pharmaceuticals, and the increasing importance of at-home healthcare services.

Regulatory Implications

The company faces significant regulatory oversight from bodies like the FDA and CMS. Compliance with evolving healthcare laws, data privacy regulations (like HIPAA), and drug pricing policies is critical. Non-compliance can lead to substantial fines, legal challenges, and reputational damage, impacting financial performance and market access.

What Investors Should Do

  1. Review the Compensation Discussion and Analysis (CD&A) on page 42.
  2. Evaluate the strategic rationale and financial impact of recent acquisitions.
  3. Monitor the impact of customer contract expirations on revenue and cash flow.
  4. Consider the company's capital allocation strategy.

Key Dates

Glossary

GAAP
Generally Accepted Accounting Principles. A common set of accounting standards and procedures used in financial reporting. (Used to report the company's official financial earnings and EPS, providing a standardized view of performance.)
Non-GAAP
Financial measures that exclude certain items from GAAP results, often to provide a clearer view of core operating performance. (Used to present operating earnings and EPS, highlighting the company's underlying business performance excluding specific one-time or non-recurring items.)
Diluted EPS
Earnings per share calculated by dividing net income by the total number of diluted shares outstanding, including potential shares from stock options and convertible securities. (A key metric for investors to assess profitability on a per-share basis, reflecting the impact of all potential share dilution.)
Net Working Capital
The difference between a company's current assets and current liabilities. It is a measure of operational liquidity. (The unwinding of negative net working capital from OptumRx contracts impacted operating cash flow, highlighting its importance in financial performance.)
MSO Platforms
Management Services Organization platforms. These are entities that provide management and administrative services to healthcare providers. (Cardinal Health is investing in these platforms as part of its growth strategy in Specialty areas like autoimmune, urology, and oncology.)
Goodwill Impairment
A charge taken when the carrying value of goodwill on a company's balance sheet exceeds its fair value, indicating a loss in value of an acquired asset. (Favorable comparisons to prior year's goodwill impairment contributed to the significant year-over-year increase in GAAP operating earnings and EPS.)

Year-Over-Year Comparison

Fiscal year 2025 shows a significant increase in profitability, with GAAP operating earnings up 83% and GAAP diluted EPS up 87%, largely due to a favorable comparison to the prior year's goodwill impairment. Non-GAAP operating earnings increased 15% and non-GAAP diluted EPS rose 9%. However, revenue saw a 2% decrease year-over-year, primarily driven by the expiration of key pharmaceutical distribution contracts. Operating cash flow declined by 37% due to the unwinding of net working capital related to these contracts. New risks related to strategic acquisitions and continued market competition are present, while the company also highlights its shareholder engagement efforts.

Filing Stats: 4,277 words · 17 min read · ~14 pages · Grade level 14.5 · Accepted 2025-09-16 06:25:59

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 40 PROPOSAL 2 — Advisory Vote to Approve the Compensation of Our Named Executive Officers 41 Compensation Discussion and Analysis 42 Human Resources and Compensation Committee Report 58

Executive Compensation Tables

Executive Compensation Tables 59 Pay Ratio Disclosure 70 Pay Versus Performance 71 Equity Compensation Plan Information 75 AUDIT COMMITTEE MATTERS 76 PROPOSAL 3 — Ratification of Appointment of Ernst & Young LLP as Independent Auditor 76 Audit Committee Report 76 Fees Paid to Ernst & Young LLP 77 Policy on Pre-Approval of Services Provided by Ernst & Young LLP 77 SHARE OWNERSHIP INFORMATION 78 OTHER MATTERS 79 General Information About the Annual Meeting 79 Communicating with the Board 81 Shareholder Recommendations for Director Nominees 82 Submitting Proxy Proposals and Director Nominations for the Next Annual Meeting of Shareholders 82 Corporate Governance Documents 83 Transfer Agent 83 ANNEX A: USE OF NON-GAAP FINANCIAL MEASURES A- 1 Exclusions from Fiscal 2025 Non-GAAP Financial Measures A- 1 Fiscal 202 5 GAAP to Non-GAAP Reconciliations A- 2 Definitions A- 2 CARDINAL HEALTH 2025 Proxy Statement 1 LETTER TO CARDINAL HEALTH SHAREHOLDERS SEPTEMBER 16, 2025 Fiscal 2025 was a strong and transformative year for Cardinal Health. We accelerated our momentum, executing against our clear strategy and delivering on our plans with disciplined execution. Our focus on driving simplification and operational efficiencies in our core while investing strategically for growth is enabling our continued evolution as we meet the needs of our customers and patients. CONTINUED STRATEGIC FOCUS ON MAXIMIZING SHAREHOLDER VALUE We made significant progress against our strategic priorities this past year, accelerating our momentum through organic and inorganic investments. With a focus on growing the core of our legacy businesses, we increased investment to enable the modernization and expansion of our distribution footprint, while enhancing our customer service capabilities and adding capacity across our networks. We also completed strategic acquisitions during the fiscal year in our Pharmaceutical and Specialty Solutio

Executive compensation

Executive compensation Sustainability initiatives 50% Total Contacted (1) 32% Total Engaged (1) 30% Director Engaged (1) (1) Represents percentage of outstanding shares as of June 30, 2025. For more information on our approach to shareholder engagement and our fiscal 2025 governance engagement efforts, see pages 36 and 37 . For more information on our shareholder engagement efforts with respect to executive compensation, see page 43 of the Compensation Discussion and Analysis ("CD&A"). Virtual Annual Meeting TIME AND DATE Wednesday, November 5, 2025 8:00 a.m. Eastern Time PLACE Virtual Meeting www.virtualshareholdermeeting.com/CAH2025 RECORD DATE September 8, 2025 This year's Annual Meeting will be conducted virtually. You will be able to participate in the virtual Annual Meeting online, vote your shares electronically, and submit questions during the meeting by visiting www.virtualshareholdermeeting.com/CAH2025 and entering the 16-digit control number included in the notice of internet availability of proxy materials, voting instruction form, or proxy card that was sent to you with this proxy statement. If you do not have a 16-digit control number, you may still attend the meeting as a guest in listen-only mode. To attend as a guest, please visit www.virtualshareholdermeeting.com/CAH2025 and enter the information requested on the screen to register as a guest. Note that you will not have the ability to vote or ask questions during the meeting if you participate as a guest. For further information on how to attend and participate in the virtual Annual Meeting, please see "Other Matters" beginning on page 79 in this proxy statement. 10 CARDINAL HEALTH 2025 Proxy Statement PROXY SUMMARY Roadmap to Voting Matters Roadmap to Voting Matters Shareholders will be asked to vote on the following proposals at the Annual Meeting: Proposal Board Recommendation Page Reference PROPOSAL 1: to elect the 12 director nominees named in this proxy s

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing